hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361563, orgStudyIdInfo id: CA209-1442, briefTitle: Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-05, primaryCompletionDateStruct date: 2024-01-25, completionDateStruct date: 2024-01-25, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Bristol-Myers Squibb, class: INDUSTRY, descriptionModule briefSummary: The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab., conditionsModule conditions: Upper Gastrointestinal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 250, type: ACTUAL, armsInterventionsModule interventions name: Nivolumab, outcomesModule primaryOutcomes measure: Participant sociodemographics, primaryOutcomes measure: Participant Eastern Cooperative Oncology Group (ECOG) score, primaryOutcomes measure: Participant histology results, primaryOutcomes measure: Participant comorbidities, primaryOutcomes measure: Participant tumour location, primaryOutcomes measure: Date of tumour resection, primaryOutcomes measure: Participant primary upper gastrointestinal cancer diagnosis, secondaryOutcomes measure: Initial nivolumab dosage prescribed to participants, secondaryOutcomes measure: Number of nivolumab treatments received, secondaryOutcomes measure: Nivolumab dosage modification, secondaryOutcomes measure: Nivolumab treatment duration, secondaryOutcomes measure: Reason for participant discharge, secondaryOutcomes measure: Participant adverse events (AEs), secondaryOutcomes measure: Management of participant adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bayshore Specialty Rx Ltd., city: Mississauga, state: Ontario, zip: L5K 2L3, country: Canada, geoPoint lat: 43.5789, lon: -79.6583, hasResults: False
protocolSection identificationModule nctId: NCT06361537, orgStudyIdInfo id: CONE-02, briefTitle: Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Octapharma, class: INDUSTRY, descriptionModule briefSummary: Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks, conditionsModule conditions: Acute Hereditary Angio Edema, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 124, type: ESTIMATED, armsInterventionsModule interventions name: OCTA-C1-INH, interventions name: Placebo, outcomesModule primaryOutcomes measure: Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants., secondaryOutcomes measure: Percentage of participants responding to treatment, secondaryOutcomes measure: Time to beginning of unequivocal symptom relief at all sites involved, secondaryOutcomes measure: Changes in symptom severity at the defining site by VAS severity rating, eligibilityModule sex: ALL, minimumAge: 2 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361524, orgStudyIdInfo id: 44967, secondaryIdInfos id: 5F32HL143916, type: NIH, link: https://reporter.nih.gov/quickSearch/5F32HL143916, secondaryIdInfos id: 856341, type: OTHER_GRANT, domain: American Heart Association, briefTitle: Gut Microbiome Profiling in Patients With Chronic Heart Failure, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2018-08-01, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), collaborators name: American Heart Association, descriptionModule briefSummary: The goal of this observational study is to learn about the composition and function of the gut microbiome in adults with chronic heart failure with reduced ejection fraction. The main questions the study aims to answer are:1. How does the gut microbiome and its interactions with the host change over time in adults with chronic heart failure?2. How do these changes relate to heart failure disease severity and complications?, conditionsModule conditions: Heart Failure With Reduced Ejection Fraction, conditions: Nonischemic Cardiomyopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Advanced heart failure-associated microbiome signatures, primaryOutcomes measure: Temporal changes in the gut microbiome community composition in chronic heart failure, secondaryOutcomes measure: Comprehensive longitudinal metabolome profile in chronic heart failure, secondaryOutcomes measure: Comprehensive longitudinal cytokine profile in chronic heart failure, secondaryOutcomes measure: Longitudinal change in New York Heart Association (NYHA) functional class, secondaryOutcomes measure: Longitudinal change in the self-reported functional status, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford University, city: Stanford, state: California, zip: 94305-5210, country: United States, geoPoint lat: 37.42411, lon: -122.16608, hasResults: False
protocolSection identificationModule nctId: NCT06361511, orgStudyIdInfo id: 2023H0284, briefTitle: The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2029-05-01, completionDateStruct date: 2030-05-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Ohio State University, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil., conditionsModule conditions: Sarcopenia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: High Linoleic Acid Foods, interventions name: High Oleic Acid Foods, outcomesModule primaryOutcomes measure: Changes is leg extensor muscle strength, secondaryOutcomes measure: Changes in quadriceps muscle volume, secondaryOutcomes measure: Change in maximum leg press strength, secondaryOutcomes measure: Change in leg fatiguability, secondaryOutcomes measure: Change in muscle mitochondria function, secondaryOutcomes measure: Changes in cardiolipin species, secondaryOutcomes measure: Changes in grip strength, secondaryOutcomes measure: Changes in gait speed, secondaryOutcomes measure: Changes in chair rise time, secondaryOutcomes measure: Changes in stair climb power, secondaryOutcomes measure: Change in short physical performance battery score, secondaryOutcomes measure: change in blood fatty acids, otherOutcomes measure: Association of changes in plasma linoleic acid with muscle function, otherOutcomes measure: Association of changes in plasma linoleic acid with muscle strength, otherOutcomes measure: Association of changes in plasma linoleic acid with muscle volume, otherOutcomes measure: Association of changes 4-LA-cardiolipin with muscle function, otherOutcomes measure: Association of changes 4-LA-cardiolipin with muscle strength, otherOutcomes measure: Association of changes 4-LA-cardiolipin with muscle volume, otherOutcomes measure: Association of changes mitochondria function with muscle volume., otherOutcomes measure: Association of changes mitochondria function with muscle function, otherOutcomes measure: Association of changes mitochondria function with muscle strength., eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 80 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Ohio State University, city: Columbus, state: Ohio, zip: 43210, country: United States, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06361498, orgStudyIdInfo id: 23-3115, briefTitle: Ultrasound for Evaluation of Percutaneous G-tube Position, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare using ultrasound imaging to look at the position of the gastrostomy tube (GT) against fluoroscopic imaging in pediatric patients who had a recent GT tube replacement.The main questions it aims to answer are:* If ultrasound is just as accurate as fluoroscopy to assess the GT position.* If ultrasound takes less time than fluoroscopy to assessing the GT position.Participants will be imaging using ultrasound to assess GT positioning before their standard of care fluoroscopic imaging., conditionsModule conditions: Gastrostomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound Imaging, outcomesModule primaryOutcomes measure: Proportion of Ultrasound that Agree with Fluoroscopy with Respect to Identifying the GT Location, secondaryOutcomes measure: Sensitivity of ultrasound (US) to determine the visualization of GT leakage, secondaryOutcomes measure: Specificity of ultrasound (US) to determine the visualization of GT leakage, secondaryOutcomes measure: Duration of ultrasound (US) to complete evaluation of GT position, eligibilityModule sex: ALL, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: University of North Carolina at Chapel Hill, city: Chapel Hill, state: North Carolina, zip: 27599, country: United States, contacts name: Hannah P Mignosa-Martin, role: CONTACT, phone: 919-843-1670, email: hannah_mignosa@med.unc.edu, contacts name: Desma Jones, role: CONTACT, phone: 9198439463, email: desma_jones@med.unc.edu, contacts name: William Pryor, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06361459, orgStudyIdInfo id: NL83858.058.12, briefTitle: Stop Smoking in Spine Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-06, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Leiden University Medical Center, class: OTHER, collaborators name: Medical Center Haaglanden, collaborators name: Haga Hospital, collaborators name: Alrijne Hospital, collaborators name: Spaarne Gasthuis, descriptionModule briefSummary: Patients that are subjected to a medium complex surgical intervention in neck (posterior) or lumbar spine (posterior) with instrumentation are motivated to stop smoking. The outcome data of patients that stop and that continue smoking will be compared. A group of non smokers is evaluated as a control group. Particularly clinical outcome is evaluated, as well as radiological outcome., conditionsModule conditions: Smoking Cessation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: three study groups: group that does not smoke, group that smokes and stops, group that smokes and does not stop, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule interventions name: Stop smoking, outcomesModule primaryOutcomes measure: ODI or NDI, secondaryOutcomes measure: VAS leg or arm pain, secondaryOutcomes measure: HADS, secondaryOutcomes measure: EuroQol, secondaryOutcomes measure: perceived recovery, secondaryOutcomes measure: radiological evaluation for fusion, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Leiden University Medical Centre, status: RECRUITING, city: Leiden, state: Zuid Holland, zip: 2300RC, country: Netherlands, contacts name: carmen vleggeert-lankamp, MD MSc PhD, role: CONTACT, phone: +31630925428, email: cvleggeert@lumc.nl, geoPoint lat: 52.15833, lon: 4.49306, hasResults: False
protocolSection identificationModule nctId: NCT06361433, orgStudyIdInfo id: R5-11, briefTitle: Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage, acronym: RAINBOW-Hx, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Hokkaido University Hospital, class: OTHER, collaborators name: Japan Agency for Medical Research and Development, descriptionModule briefSummary: The goal of this clinical trial is to test intracerebral transplantation of stem cell product in patient with chronic intracerebral hemorrhage. The main questions aims to answer are:* The safety of the product* The efficacy of the product, conditionsModule conditions: Intracerebral Hemorrhage, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: HUFF-01, outcomesModule primaryOutcomes measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, secondaryOutcomes measure: Change in mRS examination, secondaryOutcomes measure: Change in NIHSS examination, secondaryOutcomes measure: Change in FIM examination, secondaryOutcomes measure: Change in Fugl-Myer examination, secondaryOutcomes measure: Change in Barthal index examination, secondaryOutcomes measure: Change in FDG-PET examination, secondaryOutcomes measure: Change in IMZ-SPECT examination, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hokkaido University Hospital, status: RECRUITING, city: Sapporo, state: Hokkaido, zip: 0608638, country: Japan, contacts name: Masahito Kawabori, role: CONTACT, phone: +81117065987, email: masahitokawabori@yahoo.co.jp, geoPoint lat: 43.06667, lon: 141.35, hasResults: False
protocolSection identificationModule nctId: NCT06361420, orgStudyIdInfo id: 2023YF051-01, briefTitle: Driving Pressure-guided Lung Protective Ventilation, acronym: DPV, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-26, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Yong Lin, PhD, class: OTHER, descriptionModule briefSummary: The study, named as "The Efficacy of Driving Pressure-guided Lung Protective Ventilation in Surgical Repair of Acute Type A Aortic Dissection: an open-label, randomized control clinical trial", aims to investigate whether driving pressure-guided lung protective ventilation can reduce postoperative oxygenation function in patients who have undergone surgical repair of acute type A aortic dissection. The primary outcomes is the incidence of postoperative hypoxemia (a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio less than 300 mm Hg or a peripheral blood oxygen saturation less than 93% at any concentration of inspiratory oxygen) within 7 days after the surgery., conditionsModule conditions: Hypoxemia, conditions: Ventilator Lung, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: open, randomised control trial, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 43, type: ESTIMATED, armsInterventionsModule interventions name: Driving pressure-guided positive end expiratory pressure, interventions name: Optimal oxygenation-guided positive end expiratory pressure, interventions name: Ventilation strategy, interventions name: Management of hypoxemia, outcomesModule primaryOutcomes measure: The incidence of postoperative hypoxemia, secondaryOutcomes measure: The trend of perioperative oxygenation function, secondaryOutcomes measure: Postoperative pulmonary complications except hypoxemia, secondaryOutcomes measure: Early/late death, secondaryOutcomes measure: Vasoactive-inotropic score at the end of surgery, secondaryOutcomes measure: Postoperative adverse cardiovascular events, secondaryOutcomes measure: Length of stay in intensive care unit, secondaryOutcomes measure: Ventilation assistance time, secondaryOutcomes measure: Postoperative extrapulmonary complications, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian medical university union hospital, status: RECRUITING, city: Fuzhou, state: Fujian, zip: 350001, country: China, contacts name: Yong Lin, MD, role: CONTACT, phone: 13805064575, email: birdman1983@163.com, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06361407, orgStudyIdInfo id: 2023-A02464-41, briefTitle: Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia, acronym: SensoSchiz, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-04-30, completionDateStruct date: 2028-02-28, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Centre Psychothérapique de Nancy, class: OTHER, collaborators name: Institut National de la Santé Et de la Recherche Médicale, France, descriptionModule briefSummary: Disturbances in the sense of self and time could play an important role in the development of psychotic symptoms. Previous work has shown that patients have difficulty preparing to process information on the scale of a second, but are abnormally disturbed by slightly asynchronous information on the millisecond scale. In both cases, the anomalies could explain the patients' unusual experience of time. The hypothesis in neurotypical patients is that small delays or asynchronies asynchronies are treated as irrelevant information and ignored and ignored, whereas in patients suffering from schizophrenia they would disrupt the flow of time. This hypothesis is tested with a new visual illusion., conditionsModule conditions: Schizophrenia, conditions: Sensory Processing Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Individuals with schizophrenia will be tested in parallel with neurotypicals, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, maskingDescription: The group will be masked at the stage of data analysis. It cannot be masked at the prior stages, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Illusion task, outcomesModule primaryOutcomes measure: Effect of a millisecond-level trajectory perturbation, secondaryOutcomes measure: Baseline rate of illusion, secondaryOutcomes measure: Effect of a rebound (top-down, conscious influence), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False